Professor Zoe Winters

Consultant Breast Cancer Surgeon and Breast Specialist. .......(London Breast Health)

[Professor Zoe Winters @drzoewinters]

Cyclin dependent Kinase inhibitors (CDKIs) are currently used with endocrine treatments that block ER+ breast cancers

In more advanced breast cancers = HER2 positive, CDKIs double the length of progression free survival when combined with (Letrozole).
https://t.co/hZePjNvLOR

[Professor Zoe Winters @drzoewinters]

https://t.co/KiTemwkOn4

Consolidating 10 years of adjuvant (AIT) significantly reduces risks of breast cancer recurrences (both local & distant).

Benefits also occur with 5 years of upfront Tamoxifen, followed by 5 years of AIT.

Bone health discussion to be had.

[Professor Zoe Winters @drzoewinters]

https://t.co/lRUTWHZTt8

[Professor Zoe Winters @drzoewinters]

Neoadjuvant Deruxtecan or Trastuzumab is an antibody-drug conjugate that optimises breast cancer cell killing in HER positive and HR positive early or high risk breast cancers.

The overall aim of achieving a significant pCR was 67% versus 56% after SOC chemotherapy with THP.

[Professor Zoe Winters @drzoewinters]

Breast cancer surgeons are mindful of reducing or omitting armpit surgery in patients that meet evidence-based criteria. We aim to follow the current randomised trial data, including large published data sets and to offer these options to all eligible women with breast cancer.

[Professor Zoe Winters @drzoewinters]

Low risk DCIS should not be regarded as “cancer”

8-year risk of a cancer event following a DCIS diagnosis doesn’t exceed 11%, and is comparable to benign atypia

We require effective risk stratification tools and shared decision-making

https://t.co/D5SFq8lnp2

[Professor Zoe Winters @drzoewinters]

https://t.co/pGWI1wxN9n

Modern combination HRT (oestrogen and progesterone) use in women over 55 years is predicted to increase breast cancers risks slightly, equivalent to excess alcohol (more than 10g per day; to result in 1 extra cancer in 100 women)

[Professor Zoe Winters @drzoewinters]

There is no 10 year overall survival benefit for chest wall radiotherapy after mastectomy and axillary surgery; in the majority of women with intermediate risk breast cancer (clinical stage 1 or 2)

https://t.co/a6MdgfvPBL

[Professor Zoe Winters @drzoewinters]

Early detection of the ER+ resistance gene ESR1 at 2 years after endocrine treatment improves outcomes using Camizestran.

https://t.co/qZnOuDT3O9

[Professor Zoe Winters @drzoewinters]

This stance is a gamechanger in de-escalating a technique that carries side effects & has quality of life issues. We need to wait & see whether omission of SLNB in early BC remains compatible with varying doses of breast radiotherapy in women at 50 plus.
https://t.co/pnsSaILn9q

[Professor Zoe Winters @drzoewinters]

Reporting individual women's mammogram breast tissue density score; either a C or D (BIRADS A-D), therefore "dense" mandates additional breast screening tests and should be practised throughout the UK.

https://t.co/jcac8p1Lqw

[Professor Zoe Winters @drzoewinters]

US women must be told breast density after mammogram, says FDA https://t.co/ElEtbyDLl5

I wholeheartedly endorse this practice and look forward to this becoming the norm in the UK

[Professor Zoe Winters @drzoewinters]

News from San Antonio Breast Cancer meeting December 2024 – helping older women avoid axillary surgery safely

https://t.co/N5d9obJaYE

[Professor Zoe Winters @drzoewinters]

Clinicians need to integrate discussions on genitourinary symptoms in breast cancer survivors, and also clarify referral pathways that formerly link Oncologists and Menopause specialists

[Professor Zoe Winters @drzoewinters]

Clinicians are increasingly faced with menopause induced issues after breast cancer treatment.

A new pilot study called VIBRA, is evaluating the clinical benefits of vaginal prasterone or DHEA in breast cancer survivors, which may be the future.

[Professor Zoe Winters @drzoewinters]

A breast lump is the most common symptom of breast cancer.

What defines a lump?
What do you look for?
How do you self examine?

All perceived lumps, need to be clinically checked to rule out cancer.

https://t.co/MlrenHcQzR

[Professor Zoe Winters @drzoewinters]

I am humbled and thrilled to be awarded this certificate of excellence by @iwantgreatcare

I couldn't do it without the excellent team I work with at each of the hospitals for providing the best possible care for our patients.

#cofexcellence2024

[Professor Zoe Winters @drzoewinters]

https://t.co/EymltyZXhq via @YouTube
Professor Martha Hickey describes how menopause is not one thing for all women in terms of its definition or how it feels - therefore there cannot be one treatment for all. Keep one's views based on emerging knowledge and clinical evidence

[Professor Zoe Winters @drzoewinters]

We are delighted to support the use of this new anti HER2 drug called Pyrotinib for women with metastatic Stage 4 breast cancer.

Pyrotinib effectively blocks all HER2 receptors and doubles disease free survival from 12 to 24 months.

Amazing work

[Professor Zoe Winters @drzoewinters]

Post Menopausal weight gain is a significant risk factor that increases risks of breast cancer by 20-60%, whereas weight loss after menopause is associated with a decreased risk of breast cancer.
https://t.co/E0Z5j3lbOk